Cephalon published its financial results for 2009 this week, revealing record figures and a tenth annual consecutive rise in sales.
Net sales reached $2.152 billion (1.37 billion pounds) - an 11 per cent increase compared to the $1.943 billion declared in 2008.
Adjusted net income for full year 2009 was $469 million, a 28 per cent rise from the previous year.
This surpassed the organisation's guidance range of $457 million to $464 million for 2009.
Frank Baldino, chairman and chief executive officer of the company, said: "For the year we reported positive clinical study results on several of our drug candidates, advanced five new compounds into man and continued to acquire promising assets."
He added that it will continue to work towards a diversified business for its shareholders.
In other Cephalon news, the firm revealed that it plans to acquire the privately held Swiss firm Mepha AG - an agreement which also includes the latter organisation's subsidiaries.
NEWS BY INDUSTRY
